Is there a Bearish outlook for TrovaGene, Inc. (NASDAQ:TROV) this week?

February 15, 2018 - By Adrian Erickson

 Is there a Bearish outlook for TrovaGene, Inc. (NASDAQ:TROV) this week?
Investors sentiment increased to 0.85 in 2017 Q3. Its up 0.42, from 0.43 in 2017Q2. It is positive, as 10 investors sold TrovaGene, Inc. shares while 10 reduced holdings. 9 funds opened positions while 8 raised stakes. 5.05 million shares or 53.72% more from 3.29 million shares in 2017Q2 were reported.
Sabby Management Ltd Liability Com holds 0.08% or 1.69M shares in its portfolio. Meeder Asset Mgmt owns 2,582 shares or 0% of their US portfolio. Virtu Ltd accumulated 79,050 shares or 0% of the stock. Royal State Bank Of Canada holds 220 shares or 0% of its portfolio. Plante Moran Fincl Advisors Limited Liability has invested 0% of its portfolio in TrovaGene, Inc. (NASDAQ:TROV). Elkhorn Ltd Partnership reported 0.14% of its portfolio in TrovaGene, Inc. (NASDAQ:TROV). Vanguard Group Inc has 0% invested in TrovaGene, Inc. (NASDAQ:TROV) for 849,429 shares. Berson & Corrado Invest Ltd Liability Corporation reported 20,000 shares. Blackrock holds 0% or 403,005 shares in its portfolio. California Pub Employees Retirement Systems holds 77,200 shares or 0% of its portfolio. Two Sigma Securities Ltd Liability Corp owns 24,226 shares or 0% of their US portfolio. 149,843 were accumulated by Geode Management. Millennium Management Lc holds 342,343 shares or 0% of its portfolio. Bnp Paribas Arbitrage reported 0% stake. Citadel Ltd Liability Co reported 10,660 shares or 0% of all its holdings.

TrovaGene, Inc. (NASDAQ:TROV) Ratings Coverage

Among 8 analysts covering TrovaGene (NASDAQ:TROV), 1 have Buy rating, 1 Sell and 6 Hold. Therefore 13% are positive. TrovaGene had 18 analyst reports since August 14, 2015 according to SRatingsIntel. The firm has “Neutral” rating by Janney Capital given on Friday, March 11. On Thursday, August 10 the stock rating was maintained by Maxim Group with “Buy”. The firm has “Outperform” rating given on Friday, August 14 by Leerink Swann. On Tuesday, March 29 the stock rating was maintained by Avondale with “Market Perform”. Maxim Group maintained the shares of TROV in report on Wednesday, August 16 with “Buy” rating. The firm earned “Neutral” rating on Monday, April 25 by Piper Jaffray. Maxim Group maintained TrovaGene, Inc. (NASDAQ:TROV) on Tuesday, June 27 with “Buy” rating. The company was maintained on Monday, June 12 by Maxim Group. Cantor Fitzgerald downgraded it to “Hold” rating and $5 target in Monday, April 25 report. The stock of TrovaGene, Inc. (NASDAQ:TROV) earned “Sector Perform” rating by Leerink Swann on Tuesday, April 26. Below is a list of TrovaGene, Inc. (NASDAQ:TROV) latest ratings and price target changes.

21/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $1.0 Initiate
10/11/2017 Broker: Maxim Group Old Rating: Buy New Rating: Hold Downgrade
22/08/2017 Broker: Maxim Group Rating: Buy New Target: $4.0 Maintain
16/08/2017 Broker: Maxim Group Rating: Buy New Target: $4.0 Maintain

The stock decreased 4.77% or $0.0164 during the last trading session, reaching $0.3276. About 1.95 million shares traded or 1.17% up from the average. TrovaGene, Inc. (NASDAQ:TROV) has declined 83.95% since February 15, 2017 and is downtrending. It has underperformed by 100.65% the S&P500.

Trovagene, Inc., a molecular diagnostic company, focuses on the development and commercialization of proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research, and medical testing in various clinical disciplines in the United States. The company has market cap of $17.29 million. The firm intends to enhance the treatment outcomes for cancer patients through its proprietary technology to detect and quantitatively monitor circulating tumor DNA using urine or blood samples. It currently has negative earnings. It offers Precision Cancer Monitoring (PCM) platform, which provides cancer monitoring by tracking and quantifying levels of ctDNA from either urine or blood samples, as well as intends to offer clinical information beyond the current standard of care.

More recent TrovaGene, Inc. (NASDAQ:TROV) news were published by: Streetinsider.com which released: “Trovagene (TROV) Presents Data Showing Synergy of PCM-075 in Combination with …” on February 09, 2018. Also Prnewswire.com published the news titled: “Trovagene Announces Activation of Two Additional Clinical Trial Sites to …” on February 13, 2018. Prnewswire.com‘s news article titled: “Trovagene Announces Initiation of UNITE Phase 2 Clinical Trial of PCM-075 in …” with publication date: January 24, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.